Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Petrie

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Leukemia|October 3, 2019
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLMelanie Kahl, Annamaria Brioli, Martin Bens, et al.
Leukemia|January 18, 2020
Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLMelanie Kahl, Annamaria Brioli, Martin Bens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Molecular Cancer Therapeutics|June 17, 2015
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerYeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, et al.
Science Translational Medicine|March 31, 2012
Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like proteinTao Zhen, Chuan-Feng Wu, Ping Liu, et al.
Nature Medicine|March 13, 2012
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemiaTino Schenk, Weihsu Claire Chen, Stefanie Göllner, et al.
Nature Genetics|March 15, 2005
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerMario F Fraga, Esteban Ballestar, Ana Villar-Garea, et al.
Cancer Cell|December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseRebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Leukemia|October 3, 2019
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLMelanie Kahl, Annamaria Brioli, Martin Bens, et al.
Leukemia|January 18, 2020
Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLMelanie Kahl, Annamaria Brioli, Martin Bens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Molecular Cancer Therapeutics|June 17, 2015
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerYeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, et al.
Science Translational Medicine|March 31, 2012
Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like proteinTao Zhen, Chuan-Feng Wu, Ping Liu, et al.
Nature Medicine|March 13, 2012
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemiaTino Schenk, Weihsu Claire Chen, Stefanie Göllner, et al.
Nature Genetics|March 15, 2005
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerMario F Fraga, Esteban Ballestar, Ana Villar-Garea, et al.
Cancer Cell|December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseRebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.
Pageof 3